ITGAV
Integrin alpha-V
As of the edition of 20 October 2026, ITGAV (integrin alpha-V, UniProt P06756) has 8 drugs tested at it and 9 companies on the list, 9 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P06756
- How well studied
- Chemical tools exist; no approved drug acts on it
- Where it sits in the cell
- In more than one place
- Solved structures
- 59
- Disease areas
- Cancer; Nervous system; Urinary and reproductive; Blood and lymph; Lungs and airways; Skin and connective tissue; Immune system; Infections
- Registered trials of its drugs
- 48
Drugs at this target
| Status | Count |
|---|---|
| Went quiet | 6 |
| Stopped | 2 |
| Total | 8 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Cilengitide | Stopped | Phase 3 | none listed |
| Abituzumab | Stopped | Phase 2 | none listed |
| Etaracizumab | Went quiet | Phase 2 | none listed |
| Intetumumab | Went quiet | Phase 2 | none listed |
| ATN-161 | Went quiet | Phase 2 | none listed |
| STX-100 | Went quiet | Phase 2 | none listed |
| IMGN-388 | Went quiet | Phase 1 | none listed |
| MINT-1526A | Went quiet | Phase 1 | none listed |
8 of 8 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 9 |
| Total on the list | 9 |
| Company | Route |
|---|---|
| Merck KGaA | Route A |
| AstraZeneca | Route A |
| Roche | Route A |
The other 6 companies at ITGAV
In the product9 companies in all; 6 are not named here, and no score is.
See the 9 companies at ITGAV, ranked, with the facts behind eachRequest access. Nothing is shown until you do.